Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: A multicentric retrospective study from the French group COLib.

Although this difference did not reach statistical significance, this observation is in line with findings from Yoshida, who reported in a smaller series of 23 oligometastatic CRPC patients treated for bone oligometastases (15 patients) or nodal pelvic relapse (7 patients), that the time to progression was notably different—10 months for nodal MDRT versus 4.8 months for bone MDRT.

also in 111,027 other papers